Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Acadia Pharmaceuticals Inc’s stock clocked out at $22.62, down -1.61% from its previous closing price of $22.99. In other words, the price has decreased by -$1.61 from its previous closing price. On the day, 1.33 million shares were traded. ACAD stock price reached its highest trading level at $23.045 during the session, while it also had its lowest trading level at $22.55.
Ratios:
To gain a deeper understanding of ACAD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.40. For the most recent quarter (mrq), Quick Ratio is recorded 2.83 and its Current Ratio is at 2.91. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on October 21, 2025, initiated with a Buy rating and assigned the stock a target price of $33.
On May 21, 2025, Deutsche Bank Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $35.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.Deutsche Bank initiated its Hold rating on February 11, 2025, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 15 ’25 when Schneyer Mark C. sold 3,498 shares for $23.65 per share. The transaction valued at 82,728 led to the insider holds 43,447 shares of the business.
GAROFALO ELIZABETH A. sold 1,600 shares of ACAD for $41,560 on Sep 02 ’25. The Director now owns 25,382 shares after completing the transaction at $25.98 per share. On Aug 18 ’25, another insider, Schneyer Mark C., who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 22,000 shares for $25.18 each. As a result, the insider received 554,024 and left with 40,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3816270592 and an Enterprise Value of 3110568448. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.00, and their Forward P/E ratio for the next fiscal year is 26.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.75 while its Price-to-Book (P/B) ratio in mrq is 4.64. Its current Enterprise Value per Revenue stands at 3.053 whereas that against EBITDA is 29.919.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.81, which has changed by 0.55653346 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $26.65, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is -2.23%, while the 200-Day Moving Average is calculated to be 11.01%.
Shares Statistics:
It appears that ACAD traded 2.11M shares on average per day over the past three months and 2009970 shares per day over the past ten days. A total of 168.61M shares are outstanding, with a floating share count of 167.33M. Insiders hold about 0.82% of the company’s shares, while institutions hold 100.18% stake in the company. Shares short for ACAD as of 1760486400 were 8753033 with a Short Ratio of 4.15, compared to 1757894400 on 7984950. Therefore, it implies a Short% of Shares Outstanding of 8753033 and a Short% of Float of 8.129999999999999.
Earnings Estimates
Its stock is currently analyzed by 16.0 different market analysts. The consensus estimate for the next quarter is $0.12, with high estimates of $0.27 and low estimates of -$0.01.
Analysts are recommending an EPS of between $0.76 and $0.44 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.89, with 15.0 analysts recommending between $1.93 and $0.42.
Revenue Estimates
In. The current quarter, 19 analysts expect revenue to total $276.54M. It ranges from a high estimate of $282.9M to a low estimate of $272M. As of. The current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $250.4MFor the next quarter, 19 analysts are estimating revenue of $285.42M. There is a high estimate of $297M for the next quarter, whereas the lowest estimate is $278.8M.
A total of 20 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.06B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $957.8MBased on 19 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.33B and the low estimate is $1.12B.
